

PHARMACEUTICAL 2022

CEN BIOTECH INC Rank 438 of 466









PHARMACEUTICAL 2022



CEN BIOTECH INC Rank 438 of 466

The relative strengths and weaknesses of CEN BIOTECH INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CEN BIOTECH INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 222% points. The greatest weakness of CEN BIOTECH INC is the variable Assets, Current, reducing the Economic Capital Ratio by 255% points.

The company's Economic Capital Ratio, given in the ranking table, is -235%, being 313% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	472
Cost of Goods Sold	0
Intangible Assets	6,386
Liabilities, Current	9,861
Liabilities, Non-Current	207
Other Assets	1,485
Other Compr. Net Income	-34
Other Expenses	2,727
Other Liabilities	32
Other Net Income	98
Other Revenues	627
Property and Equipment	97
Research and Development	0
Selling, General and Administrative Expense	16,901

Output Variable	Value in 1000 USD
Assets	8,441
Liabilities	10,099
Expenses	19,628
Revenues	627
Stockholders Equity	-1,658
Net Income	-18,904
Comprehensive Net Income	-18,921
Economic Capital Ratio	-235%

